VivoSeq
Other

Stage II

2

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Stage II is an early-stage landscape with 2 programs across 2 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Gynecologic Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

PreclinicalG

Gynecologic Oncology Group

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Active, not recruiting2 · 25%
Recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study
Recruiting·NNantes University Hospital·N/A·NCT07354152·40 enrolled
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Active, not recruiting·ECOG-ACRIN Cancer Research Group·Preclinical·NCT04559139·186 enrolled
Multi-Site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers
Active, not recruiting·WWake Forest University Health Sciences·Preclinical·NCT06383988·216 enrolled
Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.
Completed·TThe Netherlands Cancer Institute·Phase 1·NCT01933568·15 enrolled
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Completed·UUniversity of Arizona·Phase 2·NCT00732498·28 enrolled
Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD
Completed·QQueen's University·Phase 3·NCT01491802·17 enrolled
PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial)
Completed·UUniversity Hospital, Bordeaux·Phase 3·NCT00221702·898 enrolled
Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC
Completed·WWest China Hospital·Phase 4·NCT03712969·527 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)